The Institute for Clinical and Economic Review (ICER), an independent nonprofit based in Boston that analyzes the value of drugs and other medical services, has released a…
Takeda Pharmaceutical Co. has announced that Ninlaro (ixazomib), combined with lenalidomide and dexamethasone as a therapeutic approach for relapsed and/or refractory multiple myeloma (MM), markedly…
Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma,…
A subunit of a signaling protein may be a new therapeutic target in multiple myeloma (MM), a hematologic malignancy with high relapse rates and resulting drug resistance in patients, according…
A new class of drugs that activate a protein in cells’ endoplasmic reticulum may be used as an adjuvant therapy to treat B-cell malignancies, according to the…
Researchers at Buffalo, New York-based Roswell Park Cancer Institute revealed that knocking down individual RabGTPases (Rab) proteins in myeloma cells was sufficient to disrupt the trafficking of…
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with other institutions, identified a gene called TJP1 that could help predict which…
Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination…
The International Myeloma Foundation (IMF) has announced new funding for the first comprehensive screening study that aims to prevent myeloma before it develops. The funded study, titled “iStopMM (Iceland…
A preliminary clinical study at Johns Hopkins Kimmel Cancer Center demonstrated that antibody treatment could decrease by half the number of cancer stem cells, which…